# A Study to Learn About the Treatment LTP001 in Healthy Participants (Part A) and in Participants With PAH (Part B)

Study · id `cardio:ct-nct06649110` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT06649110](<https://clinicaltrials.gov/study/NCT06649110>), retrieved 31 October 2026. No person wrote or checked this page.

Also called: NCT06649110

Browse, organ or system: Heart; Blood vessels  
Browse, condition area: Coronary and vascular disease  

## In plain language

A phase 1/2 trial registered on ClinicalTrials.gov. The registry status is recruiting. It plans to enroll 232 participants.

## Technical summary

Registry record NCT06649110. Randomized; double masking; primary purpose treatment. Start 2024-10-24 (actual); primary completion 2028-11-29 (anticipated). Results not posted.

## Key facts

- Design: Interventional study; randomized; double masking; primary purpose treatment
- Phase: Phase 1/2
- Enrolled: 232 participants (planned count; ClinicalTrials.gov record NCT06649110, source copy `cardio:ctgov-nct06649110-2026-07-21`, retrieved 2026-10-31)
- Started: 2024-10-24 (actual) (ClinicalTrials.gov record NCT06649110, source copy `cardio:ctgov-nct06649110-2026-07-21`, retrieved 2026-10-31)
- Primary completion: 2028-11-29 (anticipated) (ClinicalTrials.gov record NCT06649110, source copy `cardio:ctgov-nct06649110-2026-07-21`, retrieved 2026-10-31)
- Completion: 2028-12-31 (anticipated) (ClinicalTrials.gov record NCT06649110, source copy `cardio:ctgov-nct06649110-2026-07-21`, retrieved 2026-10-31)
- Countries: United States; Argentina; Australia; Belgium; Brazil; Czechia; France; Germany; Greece; Italy; Latvia; Mexico; Poland; Portugal; Romania; Serbia; Spain; United Kingdom (ClinicalTrials.gov record NCT06649110, source copy `cardio:ctgov-nct06649110-2026-07-21`, retrieved 2026-10-31)
- Care setting: Not reported
- Registry status: "RECRUITING" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct06649110-2026-07-21`, retrieved 2026-10-31)

## The registry's words

- Brief title: A Study to Learn About the Treatment LTP001 in Healthy Participants (Part A) and in Participants With PAH (Part B)
- Condition: Healthy Volunteers, Pulmonary Arterial Hypertension
- Intervention (Drug): LTP
- Intervention (Drug): Placebo
- Lead sponsor: Novartis Pharmaceuticals
- Lead sponsor class: INDUSTRY

## Connected pages

- Registry condition terms include this condition: Pulmonary arterial hypertension (`cardio:pulmonary-arterial-hypertension`)
- Registry condition terms include this condition: Pulmonary hypertension (`cardio:pulmonary-hypertension`)
- Registry lists this organization as the lead sponsor: Novartis (`cardio:novartis`)

## Provenance

Content hash: 3da417d8ea1af1dabde08b69c03f4cc952a8ee2c6c9d8129dc27ba0750126236
Last substantive edit: 2026-10-31
Evidence last checked: Not recorded
